Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose Escalation, Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
Sponsor: PhytoCeutica
Terminated
This trial was terminated. No reason was provided.
A PHASE1/PHASE2 clinical study on Colorectal Neoplasms and Diarrhea, this trial is terminated or withdrawn. The trial is conducted by PhytoCeutica and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
Feb 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PhytoCeutica
For direct contact, visit the study record on ClinicalTrials.gov .